Page 358 - 2020 White Paper on the Business Environment in China
P. 358
0 White Paper on the Business Environment in China
the medicines. At the same time, the industry Works Cited
benefited because of the lack of a centralized
system for quality control. Multinationals like Bloomberg. “Pharma Firms Face Shake-up
Pfizer and AstraZeneca could win more hospital with China’s Plan to Bulk-Buy Drugs.” South
tenders for their off-patent drugs, as they could China Morning Post, South China Morning Post,
more easily offer quality assurances for their 2 Jan. 2019, www.scmp.com/news/china/society/
higher-cost medicines. That kept prices elevated article/2180378/chinas-new-drug-procurement-
throughout the pharmaceutical sector. Chinese plan-set-hit-its-pharma-firms-profit.
companies that are already heavily invested in
research and development (R&D) stand the best Burton, Patrick. “4+7: China’s New Volume-
chance of surviving the new landscape. Among Based Purchasing Policy.” PharmaBoardroom, 30
mainland shares, Jiangsu Hengrui Medicine has Jan. 2019, pharmaboardroom.com/articles/4-plus-
invested the most in research by far, amounting 7-chinas-new-volume-based-purchasing-policy/.
to 16 per cent of revenue in the latest quarter.
Guangzhou-based Yipinhong Pharmaceutical CD. “Fangchenggang Intl Medical Pilot Zone
is in second place with 8.4 per cent. Zhejiang Arouses Strong Interest .” ChinaDaily.com, China
Jingxin Pharmaceutical, Chengdu Kanghong Daily, 17 June 2019, subsites.chinadaily.com.cn/
Pharmaceutical Group and Tianjin Lisheng guangxi/2019-06/17/c_382938.htm.
Pharmaceutical have invested about 8 per cent of
sales into research (Bloomberg, Burton). CD. “Zhìhuì Yīyuàn: Smart Hospital.”
ChinaDaily.com, China Daily, 3 Apr. 2019,
www.chinadaily.com.cn/a/201904/03/
WS5ca3e7bda3104842260b40b3.html.
Cision. “111 Wins 2019 China Healthcare
Industry Best Corporate Award.” PR Newswire,
PR Newswire, 8 Aug. 2019, www.prnewswire.com/
news-releases/111-wins-2019-china-healthcare-
industry-best-corporate-award-300898447.html.
Deloitte. “China’s Healthcare Provider Market:
Riding the Waves of Reform: Deloitte China: Life
Sciences and Health Care.” Deloitte China, Deloitte
China, 21 May 2019, www2.deloitte.com/cn/en/
pages/life-sciences-and-healthcare/articles/china-
healthcare-provider-market.html.
Emergo. “CHINA – Overview of Medical Device
Industry and Healthcare Statistics.” Emergo,
Emergo, 23 Oct. 2018, www.emergobyul.com/
resources/market-china.
Liu, Angus. “Big Pharma’s off-Patent Drugs
Lose out in China’s New Price-Cutting Scheme.”
FiercePharma, 6 Dec. 2018, www.fiercepharma.
com/pharma-asia/big-pharma-s-off-patent-drugs-
lose-out-china-s-new-drug-price-cutting-scheme.
Liu, Zhihua. “Advancement in Science and
Technology to Revolutionize Medical Sector,
Experts Say.” Chinadaily.com.cn, China Daily, 22
358
the medicines. At the same time, the industry Works Cited
benefited because of the lack of a centralized
system for quality control. Multinationals like Bloomberg. “Pharma Firms Face Shake-up
Pfizer and AstraZeneca could win more hospital with China’s Plan to Bulk-Buy Drugs.” South
tenders for their off-patent drugs, as they could China Morning Post, South China Morning Post,
more easily offer quality assurances for their 2 Jan. 2019, www.scmp.com/news/china/society/
higher-cost medicines. That kept prices elevated article/2180378/chinas-new-drug-procurement-
throughout the pharmaceutical sector. Chinese plan-set-hit-its-pharma-firms-profit.
companies that are already heavily invested in
research and development (R&D) stand the best Burton, Patrick. “4+7: China’s New Volume-
chance of surviving the new landscape. Among Based Purchasing Policy.” PharmaBoardroom, 30
mainland shares, Jiangsu Hengrui Medicine has Jan. 2019, pharmaboardroom.com/articles/4-plus-
invested the most in research by far, amounting 7-chinas-new-volume-based-purchasing-policy/.
to 16 per cent of revenue in the latest quarter.
Guangzhou-based Yipinhong Pharmaceutical CD. “Fangchenggang Intl Medical Pilot Zone
is in second place with 8.4 per cent. Zhejiang Arouses Strong Interest .” ChinaDaily.com, China
Jingxin Pharmaceutical, Chengdu Kanghong Daily, 17 June 2019, subsites.chinadaily.com.cn/
Pharmaceutical Group and Tianjin Lisheng guangxi/2019-06/17/c_382938.htm.
Pharmaceutical have invested about 8 per cent of
sales into research (Bloomberg, Burton). CD. “Zhìhuì Yīyuàn: Smart Hospital.”
ChinaDaily.com, China Daily, 3 Apr. 2019,
www.chinadaily.com.cn/a/201904/03/
WS5ca3e7bda3104842260b40b3.html.
Cision. “111 Wins 2019 China Healthcare
Industry Best Corporate Award.” PR Newswire,
PR Newswire, 8 Aug. 2019, www.prnewswire.com/
news-releases/111-wins-2019-china-healthcare-
industry-best-corporate-award-300898447.html.
Deloitte. “China’s Healthcare Provider Market:
Riding the Waves of Reform: Deloitte China: Life
Sciences and Health Care.” Deloitte China, Deloitte
China, 21 May 2019, www2.deloitte.com/cn/en/
pages/life-sciences-and-healthcare/articles/china-
healthcare-provider-market.html.
Emergo. “CHINA – Overview of Medical Device
Industry and Healthcare Statistics.” Emergo,
Emergo, 23 Oct. 2018, www.emergobyul.com/
resources/market-china.
Liu, Angus. “Big Pharma’s off-Patent Drugs
Lose out in China’s New Price-Cutting Scheme.”
FiercePharma, 6 Dec. 2018, www.fiercepharma.
com/pharma-asia/big-pharma-s-off-patent-drugs-
lose-out-china-s-new-drug-price-cutting-scheme.
Liu, Zhihua. “Advancement in Science and
Technology to Revolutionize Medical Sector,
Experts Say.” Chinadaily.com.cn, China Daily, 22
358
